The Quantellect read.As of Nov 19, 2026, 15 active firms cover CME Group Inc: 7 rate it Buy or better, 6 sit at Neutral, and 2 rate it Sell or worse, a neutral consensus. Targets span $230.00 to $337.00, a moderate spread. The average target of $292.15 sits 6% below the current $310.24. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $3.32 next quarter toward $13.24 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS15 active firms
Neutral
Strong Buy00%
Buy747%
Neutral640%
Sell213%
Strong Sell00%
Based on 15 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$292.15
-5.8% downside
Average target across 13 active firms as of Nov 19, 2026 vs $310.24 current
Highest Target$337.00
Average Target$292.15
Lowest Target$230.00
Detailed analyst forecasts for CME
Showing 1–14 of 14 named analysts shown · 15 active firms in the rating projection
As of Nov 19, 2026, 7 of 15 active firms rate CME a Buy (6 Neutral, 2 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
CME EPS & revenue forecast
EPS · NEXT QUARTER
$3.32
Range $3.05 – $3.60 · 12 analysts · -1% YoY
Next period, 12 analysts expect CME Group Inc to earn $3.32 a share (range $3.05 – $3.60), versus $3.36 a year earlier. Full-year consensus is $12.40, growing to $13.24 the year after.
REVENUE · NEXT QUARTER
$1.9B
Range $1.7B – $2.0B · 12 analysts · -1% YoY
Revenue is expected to reach $1.9B (range $1.7B – $2.0B), -1.2% year-over-year. Full-year consensus is $7.1B, rising to $7.5B next year.
Top analysts covering CME Group Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on CME.
#1
Alexander Blostein
Goldman Sachs · Rank #52
Sell
$254.00-18.1% to target
Overall win rate
56%
+ Follow
#2
Benjamin Budish
Barclays · Rank #180
Neutral
$321.00+3.5% to target
Overall win rate
44%
+ Follow
#3
Patrick Moley
Piper Sandler · Rank #206
Buy
$295.00-4.9% to target
Overall win rate
44%
+ Follow
#4
Michael Cyprys
Morgan Stanley · Rank #358
Buy
$359.00+15.7% to target
Overall win rate
38%
+ Follow
#5
PO
Patrick O'Shaughnessy
Raymond James · Rank #387
Buy
$320.00+3.1% to target
Overall win rate
35%
+ Follow
CME stock forecast FAQ
What is CME's average 12-month price target?+
The 13 active firms with a live target average $292.15 for CME Group Inc over the next 12 months, ranging from a $337.00 high to a $230.00 low, as of Nov 19, 2026.
Is CME stock a Buy, Sell or Neutral right now?+
The current consensus is Neutral. Of the 15 active firms as of Nov 19, 2026, 7 rate it Buy or Strong Buy, 6 rate it Neutral, and 2 rate it Sell or Strong Sell.
What are the highest and lowest price targets for CME?+
The Street-high target is $337.00 (Morgan Stanley), and the Street-low is $230.00 (B of A Securities). The average of all 13 active-firm targets is $292.15.
How many active Wall Street firms cover CME?+
15 active firms have a recognized rating on CME Group Inc as of Nov 19, 2026, and 13 active firms carry a live 12-month price target.
Who is the most accurate analyst covering CME?+
Among analysts who currently cover CME, Alexander Blostein of Goldman Sachs has the strongest overall Quantellect track record (Rank #52). Their current call is Sell with a $254.00 target.
What is CME Group Inc's projected EPS for next quarter?+
The consensus estimate is $3.32 per share (range $3.05 – $3.60) across 12 analysts. Full-year EPS is projected at $12.40, rising to $13.24 the following year.
How much revenue is CME Group Inc expected to report next quarter?+
Consensus revenue is $1.9B (range $1.7B – $2.0B). Full-year revenue is projected at $7.1B, growing to $7.5B next year.
Have analysts been upgrading or downgrading CME lately?+
As of Nov 19, 2026, 7 of 15 active firms rate CME a Buy (6 Neutral, 2 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their CME calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.